Literature DB >> 30181209

The Protease-Dependent Mesenchymal Migration of Tumor-Associated Macrophages as a Target in Cancer Immunotherapy.

Philippe Gui1, Myriam Ben-Neji1, Ekaterina Belozertseva1, Florence Dalenc2, Camille Franchet2, Julia Gilhodes2, Arnaud Labrousse1, Elisabeth Bellard1, Muriel Golzio1, Renaud Poincloux1, Isabelle Maridonneau-Parini1, Véronique Le Cabec3.   

Abstract

Macrophage recruitment is essential for tissue homeostasis but detrimental in most cancers. Tumor-associated macrophages (TAMs) play a key role in cancer progression. Controlling their migration is, thus, potentially therapeutic. It is assumed that macrophages use amoeboid motility in vivo like other leukocytes. However, it has not yet been explored. We examined TAM migration using intravital microscopy in mouse tumors and by monitoring ex vivo tissue infiltration in human surgical samples. We demonstrated that TAMs perform protease-dependent and ROCK-independent mesenchymal migration inside mouse fibrosarcoma and breast cancer explants using their own matrix metalloproteases (MMP). In contrast, macrophages use ROCK-dependent and protease-independent amoeboid migration inside inflamed ear derma and in connective tissue at the tumor periphery. We also showed that inhibition of mesenchymal migration correlates with decreased TAM recruitment and tumor growth. In conclusion, this study elucidates how macrophages migrate in vivo, and it reveals that the MMP-dependent migration mode of TAMs provides a rationale for a new strategy in cancer immunotherapy: to target TAMs specifically through their motility. Cancer Immunol Res; 6(11); 1337-51. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30181209     DOI: 10.1158/2326-6066.CIR-17-0746

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  7 in total

Review 1.  The complex role of tumor-infiltrating macrophages.

Authors:  Anthos Christofides; Laura Strauss; Alan Yeo; Carol Cao; Alain Charest; Vassiliki A Boussiotis
Journal:  Nat Immunol       Date:  2022-07-25       Impact factor: 31.250

Review 2.  Tumour invasion and dissemination.

Authors:  Ryan Lusby; Philip Dunne; Vijay K Tiwari
Journal:  Biochem Soc Trans       Date:  2022-06-30       Impact factor: 4.919

3.  HIV-1-Infected Human Macrophages, by Secreting RANK-L, Contribute to Enhanced Osteoclast Recruitment.

Authors:  Rémi Mascarau; Florent Bertrand; Arnaud Labrousse; Isabelle Gennero; Renaud Poincloux; Isabelle Maridonneau-Parini; Brigitte Raynaud-Messina; Christel Vérollet
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 4.  Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer.

Authors:  Mehdi Chaib; Subhash C Chauhan; Liza Makowski
Journal:  Front Cell Dev Biol       Date:  2020-05-19

5.  Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.

Authors:  Hanane Mansouri; Lindsay B Alcaraz; Caroline Mollevi; Aude Mallavialle; William Jacot; Florence Boissière-Michot; Joelle Simony-Lafontaine; Valérie Laurent-Matha; Pascal Roger; Emmanuelle Liaudet-Coopman; Séverine Guiu
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

6.  M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer.

Authors:  Rui Zhao; Qianyi Wan; Yong Wang; Yutao Wu; Shuomeng Xiao; Qiqi Li; Xiaoding Shen; Wen Zhuang; Yong Zhou; Lin Xia; Yinghan Song; Yi Chen; Hanshuo Yang; Xiaoting Wu
Journal:  Oncoimmunology       Date:  2020-12-30       Impact factor: 8.110

Review 7.  Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression.

Authors:  Chloé Laplagne; Marcin Domagala; Augustin Le Naour; Christophe Quemerais; Dimitri Hamel; Jean-Jacques Fournié; Bettina Couderc; Corinne Bousquet; Audrey Ferrand; Mary Poupot
Journal:  Int J Mol Sci       Date:  2019-09-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.